標題: Titlebook: Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology; Stefano Fanti,Gopinath Gnanasegaran,Ignasi Carrió Book 2021 Springe [打印本頁] 作者: 軍械 時間: 2025-3-21 19:47
書目名稱Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology影響因子(影響力)
書目名稱Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology影響因子(影響力)學科排名
書目名稱Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology網(wǎng)絡公開度
書目名稱Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology網(wǎng)絡公開度學科排名
書目名稱Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology被引頻次
書目名稱Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology被引頻次學科排名
書目名稱Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology年度引用
書目名稱Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology年度引用學科排名
書目名稱Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology讀者反饋
書目名稱Atlas of Clinical PET-CT in Treatment Response Evaluation in Oncology讀者反饋學科排名
作者: ovation 時間: 2025-3-21 21:42
Jacqueline Schuldt,Helmut Niegemanns from nonresponders. FDG PET/CT can distinguish viable from the nonviable disease. Still, false positives do occur because of posttreatment inflammatory changes due to the uptake of FDG in macrophages and activated leukocytes. We present multiple case scenarios of FDG PET/CT in response assessment of esophageal and gastric malignancy.作者: 愛花花兒憤怒 時間: 2025-3-22 01:50 作者: Colonnade 時間: 2025-3-22 05:13 作者: 剛毅 時間: 2025-3-22 10:53 作者: hurricane 時間: 2025-3-22 13:05 作者: Mumble 時間: 2025-3-22 17:26 作者: 被詛咒的人 時間: 2025-3-22 23:10
18F-FDG PET/CT and Non 18F-FDG-PET/CT in Treatment Response Evaluation in Neuro-Oncologyo overcome some of the limitations of CE-MRI. There has been significant development in the use of PET imaging for a number of use cases particularly in the field of neuro-oncology. In this chapter, we review examples of several PET Tracers in Treatment Response Evaluation in Neuro-oncology.作者: 勤勉 時間: 2025-3-23 02:46
PET/CT in the Assessment of Treatment Response in Hepatobiliary, Gall Bladder and Pancreatic Malignase to neoadjuvant therapy and detecting recurrent disease. There are several advantages and limitations of using .F-FDG PET in the assessment of treatment response. This chapter illustrates clinical examples of .F-FDG PET/CT in the assessment of treatment response in hepatobiliary, gall bladder and pancreatic malignancies.作者: neoplasm 時間: 2025-3-23 06:43 作者: reflection 時間: 2025-3-23 10:35
Conventional Radiological and PET-CT Assessment of Treatment Response Evaluation in Chemotherapy Set as surrogate markers to determine the disease status and to strategically plan therapeutic management. The chapter includes the advantages and limitations of conventional imaging and PET/CT techniques in the assessment of treatment response to chemotherapy in various cancer types, including the criteria used and recommendations.作者: 行業(yè) 時間: 2025-3-23 16:03 作者: 反應 時間: 2025-3-23 19:45 作者: Decibel 時間: 2025-3-24 01:43
Gabriele Hooffacker,Robert Kohlick approaches appear in most recent guidelines as part of the recommendations on the appropriate use of optimal imaging in solid tumors and lymphoma. This chapter will provide a general overview of various criteria used to assess tumor response to therapy and their advantages, limitations, controversies, and challenges.作者: 蘑菇 時間: 2025-3-24 06:03
Game Theory and Multi-Agent Optimization,onventional imaging and PET/CT in the postsurgical setting of various cancer types, reviewing several guidelines and recommendations. Besides, the potential pitfalls in the image interpretation will be discussed.作者: 預知 時間: 2025-3-24 07:58 作者: LUMEN 時間: 2025-3-24 14:20 作者: Visual-Acuity 時間: 2025-3-24 18:09 作者: 鋼筆記下懲罰 時間: 2025-3-24 22:39
Gabriele Hooffacker,Robert Kohlickware and sequence design, a vast number of functional MRI parameters are available, which are at different stages of validation. Standardisation and validation remain a challenge to implementation. The chapter will cover the advantages, limitations and pitfalls of using MRI for treatment response assessment in oncology patients.作者: GLADE 時間: 2025-3-24 23:13 作者: 煞費苦心 時間: 2025-3-25 03:24
The TU Value: The Non-differentiable Case criteria for response assessment in head and neck cancers. This chapter will illustrate [.F]FDG scan examples related to treatment response, including advantages, limitations, and pitfalls in head and neck cancers.作者: Phonophobia 時間: 2025-3-25 10:03 作者: RAG 時間: 2025-3-25 12:53 作者: 慢慢沖刷 時間: 2025-3-25 18:23 作者: modest 時間: 2025-3-25 23:23
18F-FDG PET/CT in Treatment Response Evaluation in Head and Neck Cancer criteria for response assessment in head and neck cancers. This chapter will illustrate [.F]FDG scan examples related to treatment response, including advantages, limitations, and pitfalls in head and neck cancers.作者: LIMN 時間: 2025-3-26 01:05
PET/CT in Treatment Response Evaluation: Lung Cancerssessment, has several advantages over conventional imaging. In this chapter, clinical examples of the strengths and limitations of .F-FDG PET/CT in the evaluation of treatment response in lung cancers are illustrated.作者: 蕨類 時間: 2025-3-26 05:57 作者: companion 時間: 2025-3-26 09:36 作者: engagement 時間: 2025-3-26 14:54
Stefano Fanti,Gopinath Gnanasegaran,Ignasi CarrióExplores the evaluation of treatment response.Presents Case-based discussions with evidence-based teaching points.Contains High-quality images and excellent authors作者: 先驅(qū) 時間: 2025-3-26 16:48
http://image.papertrans.cn/b/image/164131.jpg作者: 最初 時間: 2025-3-27 00:12 作者: 死亡 時間: 2025-3-27 04:44 作者: 使堅硬 時間: 2025-3-27 08:54
Gabriele Hooffacker,Robert Kohlickhave a crucial role in characterizing disease, the testing activity of novel therapies, and proper evaluation of therapeutic efficacy. Traditionally, treatment response evaluation in oncology is based on comparing the size or volume of the tumor before and after treatment. The introduction of molecu作者: florid 時間: 2025-3-27 11:13 作者: 新星 時間: 2025-3-27 16:50 作者: labyrinth 時間: 2025-3-27 21:39 作者: 卵石 時間: 2025-3-27 23:40 作者: hazard 時間: 2025-3-28 02:43 作者: 責問 時間: 2025-3-28 06:43
Jean-Fran?ois Mertens,Sylvain Sorint of disease, such as CT evaluation using the Response Evaluation Criteria in Solid Tumors (RECIST). However, such measurements are of limited value following radiotherapy. The challenge of determining the presence or absence of viable tumor within residual masses following radiotherapy provides a c作者: ESO 時間: 2025-3-28 14:23 作者: esthetician 時間: 2025-3-28 16:18
https://doi.org/10.1007/978-94-017-1656-7pies in soft-tissue tumors. Computed tomography (CT) represents the most common technique employed for the assessment of response to treatment. Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (RECIST1.1) is currently adopted as tumor response criteria in most trials of solid tumors作者: TRACE 時間: 2025-3-28 20:49
The TU Value: The Non-differentiable Caserequent histological type. [.F]FDG-PET/CT imaging is useful in the management of patients with head and neck cancer. The common indications in head and neck cancer include staging, assessment of response assessment, follow-up (to differentiate relapse from treatment effects, and radiotherapy plannin作者: collateral 時間: 2025-3-29 00:32
Jean-Fran?ois Mertens,Sylvain Sorin response to treatment in lung cancer. However, FDG PET/CT is widely used for evaluating response in lung cancer treated with different modalities. Morphological imaging, like CT, cannot accurately differentiate viable residual tumour from postradiotherapy changes. The metabolic response is being ev作者: 暗諷 時間: 2025-3-29 04:59 作者: 知識分子 時間: 2025-3-29 10:02 作者: micronutrients 時間: 2025-3-29 14:55
Jacqueline Schuldt,Helmut Niegemannatients with locally advanced disease have distant metastatic disease at presentation. In general, combined chemo-radiotherapy and neoadjuvant chemotherapy before surgery are some of the approaches used to improve local control. .F-FDG PET/CT is the modality of choice to identify treatment responder作者: Indelible 時間: 2025-3-29 16:35
Christopher Lindberg,Meghan Naxer degree of uptake at the end of treatment correlates with survival. An interim assessment is being used more and more and is particularly useful in patients with Hodgkin lymphoma. It is now essential for Nuclear Medicine physicians and radiologists to be familiar with the Deauville score, a visual t作者: frivolous 時間: 2025-3-29 22:54 作者: progestin 時間: 2025-3-30 00:37 作者: 共同確定為確 時間: 2025-3-30 04:32 作者: expansive 時間: 2025-3-30 08:52 作者: 急急忙忙 時間: 2025-3-30 13:09
PET and PET-CT in Treatment Response Evaluation: Overviewing to assess response is tumor heterogeneity. In addition to its crucial clinical role for managing treatments in individual patients, response assessment by imaging is critical for oncologic drug development. Using imaging-based end points instead of survival end points can shorten the duration of作者: ingenue 時間: 2025-3-30 20:35 作者: Femine 時間: 2025-3-30 22:04
Conventional Radiological and PET-CT Assessment of Treatment Response Evaluation in Chemotherapy Setify the most efficient form of treatment. Combining imaging information with critical clinical end points has become essential in cancer therapeutics, which provides valuable information in assessing response to chemotherapy agents. Imaging characteristics and interpretation criteria are used to act作者: Offset 時間: 2025-3-31 03:12 作者: Hyperplasia 時間: 2025-3-31 07:28 作者: genesis 時間: 2025-3-31 11:01
Reporting Post-Therapy Scanspies in soft-tissue tumors. Computed tomography (CT) represents the most common technique employed for the assessment of response to treatment. Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (RECIST1.1) is currently adopted as tumor response criteria in most trials of solid tumors
